Advanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment.The developments of the molecular mechanisms on cancer progression provide insight into novel targeted th...Advanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment.The developments of the molecular mechanisms on cancer progression provide insight into novel targeted therapies,which are emerging as groundbreaking and promising cancer treatment strategies.In gynecologic malignancies,potential therapeutic targeted agents include antiangiogenic agents,poly(ADP-ribose)polymerase(PARP)inhibitors,tumor-intrinsic signaling pathway inhibitors,selective estrogen receptor downregulators,and immune checkpoint inhibitors.In this article,we provide a comprehensive review of the clinical evidence of targeted agents in gynecological cancers and discuss the future implication.展开更多
基金supported by National Major Scientific and Technological Project for“Significant New Drugs Development”in China(2018ZX09733001).
文摘Advanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment.The developments of the molecular mechanisms on cancer progression provide insight into novel targeted therapies,which are emerging as groundbreaking and promising cancer treatment strategies.In gynecologic malignancies,potential therapeutic targeted agents include antiangiogenic agents,poly(ADP-ribose)polymerase(PARP)inhibitors,tumor-intrinsic signaling pathway inhibitors,selective estrogen receptor downregulators,and immune checkpoint inhibitors.In this article,we provide a comprehensive review of the clinical evidence of targeted agents in gynecological cancers and discuss the future implication.
